Dongbo G. Tian

Qingyuan, CN 
Qingyuan, CN 

Overview

Dongbo Tian practices practicing medicine in Qingyuan, China.

Their clinical expertise encompasses Lung Adenocarcinoma, Cerebral Hypoxia, and Lung Cancer.

They are actively involved in clinical research, co-authoring 13 peer reviewed articles and participating in 2 clinical trials.

Locations

Qingyuan, China

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Experts who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

2 Clinical Trials

Investigation of the Clinical, Radiological and Biological Factors Associated With Disease Progression, Phenotypes and Endotypes of COPD in China
Investigation of the Clinical, Radiological and Biological Factors Associated With Disease Progression, Phenotypes and Endotypes of COPD in China
Enrollment Status: Completed
Publish Date: August 20, 2025
Intervention Type: Other
A Phase III, 12 Week, Randomized, Double-blind, 4 Arm Parallel Group Bridging Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination FF/UMEC/VI Once-daily Via a Dry Powder Inhaler With Dual Combination of FF/VI, Administered in Chinese Participants With Inadequately Controlled Asthma
A Phase III, 12 Week, Randomized, Double-blind, 4 Arm Parallel Group Bridging Study, Comparing the Efficacy, Safety and Tolerability of the Fixed Dose Combination FF/UMEC/VI Once-daily Via a Dry Powder Inhaler With Dual Combination of FF/VI, Administered in Chinese Participants With Inadequately Controlled Asthma
Enrollment Status: Completed
Publish Date: August 11, 2025
Intervention Type: Device, Drug
Study Drugs: FF/VI, FF/UMEC/VI
Study Phase: Phase 3
View 1 Less Clinical Trial

13 Total Publications

Efficacy and Safety of Ensifentrine in Chinese Participants With COPD: The ENHANCE-CHINA Randomized Clinical Trial.
Efficacy and Safety of Ensifentrine in Chinese Participants With COPD: The ENHANCE-CHINA Randomized Clinical Trial.
Journal: Chest
Published: October 15, 2025

Frequently Asked Questions about Dongbo G. Tian

Is Dongbo G. Tian a top-rated expert for Lung Adenocarcinoma?

MediFind is an objective health platform that identifies experts based on real-world data. Dongbo G. Tian is classified as an Experienced expert for Lung Adenocarcinoma, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

Does Dongbo G. Tian participate in research or clinical trials?

Yes. Dongbo G. Tian has published 13 articles and abstracts on conditions like Lung Adenocarcinoma. You can view a list of Dongbo G. Tian's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Tian's expertise for a condition
ConditionClose
        Want to save this expert for later?
        Sign Up
        Not sure about your diagnosis?
        Check Your Symptoms
         
         
         
         
        Learn about our expert tiers
        Learn More
        Are you the provider on this profile?
        Claim Profile